Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure

Trial Profile

Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2014

At a glance

  • Drugs Ornithine phenylacetate (Primary)
  • Indications Liver failure
  • Focus Adverse reactions
  • Sponsors Ocera Therapeutics
  • Most Recent Events

    • 28 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top